Quest Diagnostics (DGX) PT Lowered to $100 at Baird
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/12/2026
- Wall Street ends higher as SpaceX's market debut dominates
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Brent falls to lowest since March on expected peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Adobe CFO Dan Durn to depart company in June 2026
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Super Micro Computer establishes $1.25 billion stock sale agreement
Quest Diagnostics (DGX) Reports Election of Denise Morrison to Board
February 19, 2019 5:06 PM ESTQuest Diagnostics (NYSE: DGX) today announced that its Board of Directors has elected Denise M. Morrison to serve as a director, effective February 18, 2019. Including Ms. Morrison, the company's Board has 11 members.
Ms. Morrison served as President and Chief Executive Officer of Campbell... More
Quest Diagnostics (DGX) PT Lowered to $98 at Morgan Stanley
February 15, 2019 8:06 AM ESTMorgan Stanley analyst Ricky Goldwasser lowered the price target on Quest Diagnostics (NYSE: DGX) to $98.00 (from $101.00) while maintaining a Overweight rating.
... MoreQuest Diagnostics (DGX) PT Raised to $91 at UBS
February 15, 2019 7:43 AM ESTUBS raised its price target on Quest Diagnostics (NYSE: DGX) to $91.00 (from $90.00) while maintaining a Neutral rating.
... MoreQuest Diagnostics (DGX) PT Lowered to $93 at Citi
February 15, 2019 7:08 AM ESTCiti analyst Ralph Giacobbe lowered the price target on Quest Diagnostics (NYSE: DGX) to $93.00 (from $95.00) while maintaining a Neutral rating.
... MoreQuest Diagnostics (DGX) Misses Q4 EPS by 3c, Revenues; Offers FY19 EPS/Revenue Guidance Below Consensus
February 14, 2019 6:50 AM ESTQuest Diagnostics (NYSE: DGX) reported Q4 EPS of $1.36, $0.03 worse than the analyst estimate of $1.39. Revenue for the quarter came in at $1.84 billion versus the consensus estimate of $1.88 billion.
"In 2018 we grew revenues, adjusted earnings and cash from operations despite some challenges in the... More
